Swallowable Blood Detector Gets Class II Status
Published Date: 6/17/2026
Rule
Summary
The FDA is officially putting the ingestible gastrointestinal blood detection capsule into Class II, meaning it now has special safety rules but fewer hurdles than before. This change helps patients get access to this cool, innovative device faster and keeps it safe and effective. The new classification is effective June 17, 2026, and could save time and money for makers and users alike.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Easier pathway for future device makers
If you make medical devices, FDA’s De Novo classification of the ingestible gastrointestinal blood detection capsule means this device can serve as a predicate for future devices, allowing sponsors to use the less-burdensome 510(k) process instead of a De Novo or premarket approval pathway. This change is effective June 17, 2026, and the classification was applicable on February 24, 2023.
New safety and labeling requirements
The device is now Class II with specific special controls that require clinical performance testing (including comparison to endoscopy for detecting GI bleeding, capsule excretion/recovery, and all adverse events), many non-clinical tests (dimensional, performance, battery life, leak, bite, pH resistance, bioburden control, and blood detection), software validation, electrical/thermal/mechanical and electromagnetic testing, usability, biocompatibility, shelf-life demonstration, and detailed physician and patient labeling. These special controls are part of the codified rule effective June 17, 2026 (classification applicable February 24, 2023).
Premarket 510(k) submission required
Manufacturers of ingestible gastrointestinal blood detection capsules must submit a premarket notification under section 510(k); FDA has not exempted this device type under section 510(m). This premarket notification requirement applies as part of the Class II classification effective June 17, 2026 (classification applicable February 24, 2023).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20727, Medical Devices; Immunology and Microbiology Devices; Classification of the System for Detection of Nucleic Acid From Non-Viral Microorganism(s) Causing Sexually Transmitted Infections Using Home-Collected Specimens
The FDA is officially classifying home test kits that detect non-viral germs causing sexually transmitted infections as Class II devices, meaning they have special safety rules but fewer hurdles than the strictest category. This change, effective October 9, 2026, helps make these tests safer and easier to get, benefiting patients and innovators alike. If you make or use these home test kits, this update means better access and clear safety standards without extra costs or delays.
Previous / Next Documents
Previous: 2026-12149, Equal Credit Opportunity (Regulation B); Special Purpose Credit Programs; Rescission
The Consumer Financial Protection Bureau is canceling a 2020 advisory opinion about special credit programs made by for-profit companies to help certain social groups. This change affects lenders and businesses using these programs, clarifying how the Equal Credit Opportunity rules apply. The cancellation takes effect on June 17, 2026, so affected parties should review their credit policies soon to avoid confusion or legal risks.
Next: 2026-12166, Medical Devices; Radiology Devices; Classification of the Radiological Machine Learning-Based Quantitative Imaging Software With Predetermined Change Control Plan
The FDA is officially putting radiology software that uses machine learning and has a set plan for updates into a safer, easier-to-manage category called Class II. This change helps make sure the software is safe and effective while speeding up patient access to cool new tech. It’s been effective since early 2023, so companies can expect fewer hoops to jump through without extra costs or delays.